目的: 通过生物信息学方法分析甲状腺乳头状癌预后相关基因,为后续实验提供理论基础,以便进一步研究甲状腺乳头状癌发生的可能机制。方法: 利用生物信息学方法从癌症基因组图谱(the cancer genome atlas, TCGA)数据库中下载甲状腺乳头状癌和癌旁组织样本的RNA测序数据,通过差异分析获取差异基因;利用基因本体论( gene ontology,GO ) 和京都基因和基因组百科全书(Kyoto Encyclopedia of Genes Genomes, KEGG )进行差异基因生物学功能和通路富集分析;通过蛋白交互网络分析法(protein-protein interaction,PPI)筛选出关键基因;通过生存分析研究关键基因对甲状腺乳头状癌患者生存预后的影响。结果: 在TCGA数据库中共筛选出甲状腺乳头状癌患者237例,其中甲状腺乳头状癌组织212例,甲状腺癌旁组织25例。通过差异基因分析后共筛选出715个差异基因;通路富集分析显示,神经信号转导活性、逆行内源性大麻素信号为主要的信号通路;通过PPI法共筛选出18个关键基因,包含9个上调基因和9个下调基因;通过生存分析发现高表达OPRK1的患者预后较差。结论: OPRK1的表达水平变化与患者的生存时间存在显著相关性,具体机制有待进一步研究。
Objective: To analyze prognostic genes of papillary thyroid carcinoma with bioinformatics and to provide theoretical basis for subsequent experiments, so to further study the possible mechanism of papillary thyroid carcinoma. Methods: RNA sequencing data on papillary thyroid carcinoma and para-carcinoma tissue samples were downloaded from The Cancer Genome Atlas (TCGA) database with the bioinformatics method, and differential genes were obtained by differential analysis. Biological function and pathway enrichment analysis on different genes were analyzed using Gene Ontology (GO) database and the Kyoto Encyclopedia of Genes (KEGG) database. Key genes were screened by protein-protein interaction (PPI). The influence of key genes on survival and prognosis of patients with papillary thyroid carcinoma was studied with survival analysis. Results: A total of 237 cases of papillary thyroid carcinoma was screened from TCGA database, including 212 cases of papillary thyroid carcinoma tissue and 25 cases of para-thyroid carcinoma tissue. A total of 715 differential genes were screened by differential gene analysis. Pathway enrichment analysis showed that signal transduction activity and retrograde endocannabinoid signaling were the main pathways. A total of 18 key genes were screened with PPI method, including 9 up-regulated genes and 9 down-regulated genes. Survival analysis showed that patients with high expression of OPRK1 had a poor prognosis. Conclusion: The expression level of OPRK1 is significantly correlated with the survival time of patients. However, the specific mechanism needs to be further studied.
[1] Davies L, Welch HG. Current thyroid cancer trends in the United States[J]. JAMA Otolaryngol Head Neck Surg, 2014, 140(4): 317-322.
[2] Lalami Y, Awada A. Recurrent thyroid cancer: a molecular-based therapeutic breakthrough[J]. Curr Opin Oncol, 2011, 23(3): 235-240.
[3] Chereau N, Giudicelli X, Pattou F, et al. Diffuse sclerosing variant of papillary thyroid carcinoma is associated with aggressive histopathological features and a poor outcome: results of a large multicentric study[J]. J Clin Endocrinol Metab, 2016, 101(12): 4603-4610.
[4] Bikas A, Burman KD. Epidemiology of thyroid cancer[M]. Cham: Springer, 2019: 541-547.
[5] Lauss M, Kriegner A, Vierlinger K, et al. Characterization of the drugged human genome[J]. Pharmacogenomics, 2007, 8(8): 1063-1073.
[6] Zhou SL, Dai Z, Zhou ZJ, et al. Overexpression of CXCL5 mediates neutrophil infiltration and indicates poor prognosis for hepatocellular carcinoma[J]. Hepatology, 2012, 56(6): 2242-2254.
[7] Zhang W, Wang H, Sun M, et al. CXCL5/CXCR2 axis in tumor microenvironment as potential diagnostic biomarker and therapeutic target[J]. Cancer Commun, 2020, 40(2-3): 69-80.
[8] Harihar S, Ray S, Narayanan S, et al. Role of the tumor microenvironment in regulating the anti-metastatic effect of KISS1[J]. Clin Exp Metastasis, 2020, 37(2): 209-223.
[9] Savvidis C, Papaoiconomou E, Petraki C, et al. The role of KISS1/KISS1R system in tumor growth and invasion of differentiated thyroid cancer[J]. Anticancer Res, 2015, 35(2): 819-26.
[10] Ringel MD, Hardy E, Bernet VJ, et al. Metastin receptor is overexpressed in papillary thyroid cancer and activates MAP kinase in thyroid cancer cells[J]. J Clin Endocrinol Metab, 2002, 87(5): 2399-2402.
[11] Savvidis C, Papaoiconomou E, Petraki C, et al. The role of KISS1/KISS1R system in tumor growth and invasion of differentiated thyroid cancer[J]. Anticancer Res, 2015, 35(2): 819-826.
[12] Qu M, Wan S, Ren B, et al. Association between TSHR gene methylation and papillary thyroid cancer: a meta-analysis[J]. Endocrine, 2020, 69(3): 508-515.
[13] Sarkar P, Kumar S. Calcium sensing receptor modulation for cancer therapy[J]. Asian Pac J Cancer Prev, 2012, 13(8): 3561-3568.
[14] Sherman SK, Maxwell JE, Carr JC, et al. Gene expression accurately distinguishes liver metastases of small bowel and pancreas neuroendocrine tumors[J]. Clin Exp Metastasis, 2014, 31(8): 935-944.
[15] Zhang YF, Xu QX, Liao LD, et al. κ-Opioid receptor in the nucleus is a novel prognostic factor of esophageal squamous cell carcinoma[J]. Hum Pathol, 2013, 44(9): 1756-65.
[16] Chen D, Chen Y, Yan Y, et al. Down-regulation of the tumour suppressor κ-opioid receptor predicts poor prognosis in hepatocellular carcinoma patients[J]. BMC Cancer, 2017, 17(1): 1-11.
[17] Li H, Ma Z, Lei Y. The expression of kappa-opioid receptor promotes the migration of breast cancer cells in vitro[J]. BMC Anesthesiol, 2021, 21(1): 1-10.
[18] Yamamizu K, Furuta S, Hamada Y, et al. к Opioids inhibit tumor angiogenesis by suppressing VEGF signaling[J]. Sci Rep, 2013, 3(1): 1-8.
[19] Yamamizu K, Hamada Y, Narita M.κ Opioid receptor ligands regulate angiogenesis in development and in tumours[J]. Br J Pharmacol, 2015, 172(2): 268-276.
[20] Tian F, Zheng XY, Li J, et al. κ-Opioid receptor stimulation improves endothelial function via Akt-stimulated NO production in hyperlipidemic rats[J]. Sci Rep, 2016, 6(1): 1-10.
[21] Cui Y, Feng N, Gu X, et al. κ-Opioid receptor stimulation reduces palmitate-induced apoptosis via Akt/eNOS signaling pathway[J]. Lipids Health Dis, 2019, 18(1): 1-9.
[22] Dai H, Wang P, Mao H, et al. Dynorphin activation of kappa opioid receptor protects against epilepsy and seizure-induced b1rain injury via PI3K/Akt/Nrf2/HO-1 pathway[J]. Cell Cycle, 2019, 18(2): 226-237.
[23] Liu L, Yu J, Xu X. Kappa-opioid receptor agonist U50448H protects against renal ischemia-reperfusion injury in rats via activating the PI3K/Akt signaling pathway[J]. Acta Pharmacol Sin, 2018, 39(1): 97-106.
